drugset / Trial / NCT03542279

CPI Combination Therapy for Autoimmune Encephalitis

NCT03542279

Completed 70 enrolled Xuanwu Hospital, Beijing
RandomizedSingle-groupSingle-blindTreatment

Summary

Corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange (PE) are the first-line therapies for autoimmune encephalitis (AE) patients, but optimal first-line treatment strategy for different AE patients remains undetermined. The study is to compare the efficacy between pulse corticosteroid plus PE initially followed by IVIG (CPI therapy) and pulse corticosteroid plus IVIG followed by PE two weeks later (CIP therapy) in patients with severe antibody-associated autoimmune encephalitis (AE).

Timeline

Start
2020-11-25
Primary completion
2022-12-12
Completion
2024-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 500 mg Intravenous
Subject Methylprednisolone Other / unclassified 1000 mg Intravenous
Subject intravenous immunmoglobulin Protein / enzyme biologic 0.4 g/kg Intravenous